Joseph Ross, MD, MHS
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)DownloadHi-Res Photo
Cards
Education
MHS
Yale School of Medicine (2006)
Yale School of Medicine (2006)
MD
Albert Einstein College of Medicine (2001)
Albert Einstein College of Medicine (2001)
MD
Albert Einstein College of Medicine of Yeshiva University (2001)
Albert Einstein College of Medicine of Yeshiva University (2001)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Publications Overview
- 689 Publications
- 26,502 Citations
- 111 Yale Co-Authors
Education
MHS
Yale School of Medicine (2006)
Yale School of Medicine (2006)
MD
Albert Einstein College of Medicine (2001)
Albert Einstein College of Medicine (2001)
MD
Albert Einstein College of Medicine of Yeshiva University (2001)
Albert Einstein College of Medicine of Yeshiva University (2001)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Publications Overview
- 689 Publications
- 26,502 Citations
- 111 Yale Co-Authors
Education
MHS
Yale School of Medicine (2006)
Yale School of Medicine (2006)
MD
Albert Einstein College of Medicine (2001)
Albert Einstein College of Medicine (2001)
MD
Albert Einstein College of Medicine of Yeshiva University (2001)
Albert Einstein College of Medicine of Yeshiva University (2001)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Publications Overview
- 689 Publications
- 26,502 Citations
- 111 Yale Co-Authors
About
Copy Link
Titles
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)
Biography
Joseph S. Ross, MD, MHS, is a Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management), a member of the Center for Outcomes Research and Evaluation (CORE) at the Yale-New Haven Hospital, and an Co-Director of the National Clinician Scholars program (NCSP) at Yale. He completed his undergraduate degrees in biological science: neuroscience and psychology at the University of Rochester and his medical degree at the Albert Einstein College of Medicine, Bronx, NY. After completing his post-graduate training in primary care internal medicine at Montefiore Medical Center in Bronx, NY, Dr. Ross was a fellow in the Robert Wood Johnson Foundation Clinical Scholars program at Yale, earning a Master’s degree in health sciences research. Using health services research methods, Dr. Ross’s research focuses on examining factors which affect the use or delivery of recommended ambulatory care services for older adults and other vulnerable populations, evaluating the impact of state and federal policies on the delivery of appropriate and higher quality care, and addressing issues related to pharmaceutical and medical device regulation, evidence development, postmarket surveillance, and clinical adoption. In addition, he collaborates with a multi-disciplinary team of investigators under contract for the Centers for Medicare and Medicaid Services to develop statistical models that are used to measure and publicly report hospital and ambulatory care clinical outcomes using administrative data. Dr. Ross co-directs the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI), the Yale Open Data Access (YODA) Project, the Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) at Yale Law School, and leads efforts at Yale-New Haven Health System in collaboration with the National Evaluation System for health Technology. Dr. Ross is currently a Deputy Editor at JAMA, co-founder of medRxiv, Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), and a member of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) for ICER.
Last Updated on June 19, 2024.
Appointments
General Internal Medicine
ProfessorPrimaryHealth Policy & Management
ProfessorSecondaryInstitution for Social and Policy Studies
ProfessorSecondary
Other Departments & Organizations
- All Institutions
- Cancer Prevention and Control
- Center for Outcomes Research & Evaluation (CORE)
- Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT)
- General Internal Medicine
- Health Policy & Management
- Institution for Social and Policy Studies
- Internal Medicine
- National Clinician Scholars Program
- Regulatory Affairs Track
- Yale New Haven Health System
- Yale School of Public Health
- Yale Ventures
Education & Training
- MHS
- Yale School of Medicine (2006)
- Postgraduate Training
- Montefiore Medical Center (2004)
- Residency
- Montefiore Medical Center/Albert Einstein College of Medicine (2004)
- Internship
- Montefiore Medical Center/Albert Einstein College of Medicine (2004)
- MD
- Albert Einstein College of Medicine (2001)
- MD
- Albert Einstein College of Medicine of Yeshiva University (2001)
- BS
- University of Rochester (1996)
- BA
- University of Rochester (1996)
Research
Copy Link
Overview
Medical Research Interests
Delivery of Health Care; Health Services Research; Pharmaceutical Services; Quality of Health Care
Public Health Interests
Health Care Management; Health Policy; Health Systems Reform; Pharmaceuticals and Medical Devices
ORCID
0000-0002-9218-3320
Research at a Glance
Yale Co-Authors
Frequent collaborators of Joseph Ross's published research.
Publications Timeline
A big-picture view of Joseph Ross's research output by year.
Research Interests
Research topics Joseph Ross is interested in exploring.
Harlan Krumholz, MD, SM
Jeph Herrin, PhD
Reshma Ramachandran, MD, MPP, MHS
Jennifer E Miller, PhD
Jeptha Curtis, MD
Cary P Gross, MD
689Publications
26,502Citations
Quality of Health Care
Delivery of Health Care
Health Services Research
Publications
2025
Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies
Thanarajasingam G, Bhatnagar V, Noble B, Chen T, Fiero M, Hoffman R, Jeffery M, Mazza G, Mascarenhas J, Mesa R, Murugappan M, Ross J, Sidana S, Warsame R, Kluetz P, Dueck A. Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies. BMC Medical Research Methodology 2025, 25: 189. PMID: 40775758, PMCID: PMC12329971, DOI: 10.1186/s12874-025-02617-y.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCross-Sectional StudiesFemaleHematologic NeoplasmsHumansLongitudinal StudiesMaleMiddle AgedMulticenter Studies as TopicPatient Reported Outcome MeasuresQuality of LifeRandomized Controlled Trials as TopicSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationConceptsFood and Drug AdministrationHematologic malignanciesPhysical functionCAR-T cell therapyUS Food and Drug AdministrationPatient-reported physical functionCore patient-reported outcomesPROMIS-29 questionnairePatient-reported outcomesEORTC QLQ-C30CAR-TStacked bar chartsAutologous transplantationMyeloproliferative neoplasmsTolerability endpointsTreatment toleranceMultiple myelomaBackgroundThe US Food and Drug AdministrationCell therapyClinical trialsMalignancyCancer clinical trialsPatient stakeholdersPROMIS-29Fact Questionnaire308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular events779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MARON B, MCCOY R. 779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2025, 74 DOI: 10.2337/db25-779-p.Peer-Reviewed Original ResearchConceptsModerate CVD riskCVD riskType 2 diabetesCardiovascular diseaseAssociated with lower hazardRisk of cardiovascular outcomesCardiovascular disease outcomesCox proportional hazards modelsCardiovascular outcomesGlucagon-like peptide-1 receptor agonistsModerate cardiovascular riskCardiovascular risk reductionDigestive and Kidney DiseasesPeptide-1 receptor agonistsPropensity score inverse probabilityProportional hazards modelHazard of deathDepartment visitsNational Institute of DiabetesHazard of MACETrial emulationMedicare AdvantageMedicare plansComparative riskHazards model780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk
KALATHIYA U, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Diabetes 2025, 74 DOI: 10.2337/db25-780-p.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1RAAcute pancreatitisPancreatic cancerType 2 diabetesRisk of pancreatic cancerIncident acute pancreatitisMedicare fee-for-servicePancreatitis eventsComparative riskAssociated with lower riskFee-for-serviceCardiovascular disease riskGlucagon-like peptide-1 receptor agonistsModerate cardiovascular disease riskSecond-line glucose-lowering therapyAssociated with increased riskAssociated with higher riskRisk of acute pancreatitisPeptide-1 receptor agonistsPropensity score inverse probabilityDipeptidyl peptidase-4 inhibitorsOptumLabs Data WarehouseGLP-1RA therapyModerate cardiovascular riskRepresentation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time.
Miller J, Pelletiers W, Gross C, Mello M, Ramachandran R, Schwartz J, Suttiratana S, Varma T, Ross J. Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time. JCO Oncology Practice 2025, op2400563. PMID: 40493876, DOI: 10.1200/op-24-00563.Peer-Reviewed Original ResearchAltmetricConceptsFood and Drug AdministrationOncology therapeuticsLatino patientsBlack patientsTherapeutic approvalsOlder adultsRetrospective cross-sectional studyUS Food and Drug AdministrationTrial characteristicsMinoritized patientsUS patient populationSpot trialsPivotal trialsPatient demographicsPatient populationRepresentative patientsTrial enrollmentUS Census dataDrug AdministrationPatientsStudy of trialsTrialsOncologyWomenClinical trial diversityPublic Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests
Kadakia K, Ross J, Ramachandran R. Public Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests. JAMA Health Forum 2025, 6: e252233. PMID: 40540283, DOI: 10.1001/jamahealthforum.2025.2233.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsLaboratory-developed testsFood and Drug AdministrationPublic health implicationsEastern District of TexasSupreme Court's recent decisionAssociation of Molecular PathologyCourt's recent decisionUS District CourtClinical evidence of safetyRegulate laboratory-developed testsFood and Drug Administration regulationsUS Food and Drug AdministrationPublic health concernPublic health emergencyMedical Devices AuthorityChevron doctrineDistrict CourtAgency interpretationsClinical careHealth technologiesImplementing statutesComplex molecular testsLegal challengesAmendment ActRegulatory remitShareholder Payouts Among Large Publicly Traded Health Care Companies
Roy V, Amana V, Ross J, Gross C. Shareholder Payouts Among Large Publicly Traded Health Care Companies. JAMA Internal Medicine 2025, 185: 466-468. PMID: 39928316, PMCID: PMC11811864, DOI: 10.1001/jamainternmed.2024.7687.Peer-Reviewed Original ResearchAltmetricReaffirming the JAMA Network Commitment to the Health of Patients and the Public
Bibbins-Domingo K, Bonow R, Bressler N, Brubaker L, Christakis D, Christiansen S, Curfman G, Disis M, Flanagin A, Galea S, Inouye S, Josephson S, Kibbe M, Lieu T, Malani P, McDermott M, Muth C, Öngür D, Park H, Piccirillo J, Perencevich E, Perlis R, Ross J, Shinkai K, Walter K. Reaffirming the JAMA Network Commitment to the Health of Patients and the Public. JAMA 2025, 333: 1121-1122. PMID: 39977264, DOI: 10.1001/jama.2025.2405.Peer-Reviewed Original ResearchCitationsAltmetricOnline Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists
Chetty A, Chillakanti M, Ramachandran R, Ross J, Chen A. Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists. JAMA Health Forum 2025, 6: e245018. PMID: 39820389, PMCID: PMC11742527, DOI: 10.1001/jamahealthforum.2024.5018.Peer-Reviewed Original ResearchCitationsAltmetricAssessing Medicare’s Coverage With Evidence Development Program
Mooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. Assessing Medicare’s Coverage With Evidence Development Program. Health Affairs 2025, 44: 32-39. PMID: 39761464, DOI: 10.1377/hlthaff.2024.00814.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity JAMA
06/01/2023 - PresentJournal ServiceDeputy Editoractivity BMJ
2020 - 2023Journal ServiceAssociate Editoractivity JAMA Internal Medicine
04/01/2013 - 12/31/2019Journal ServiceAssociate Editoractivity Journal of General Internal Medicine
2011 - 2013Journal ServiceDeputy Editor
News
Copy Link
News
- September 02, 2025Source: Healthcare Dive
AI devices with no clinical validation tied to more recalls, study finds
- July 21, 2025
New YSPH Pilot Grants Support Innovative Interdisciplinary Research
- June 24, 2025Source: BioSpace
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
- May 05, 2025
Why Aren’t People Who Need Weight Loss Drugs Getting Them?
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Office Fax Number
Mailing Address
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Ste 405B
New Haven, CT 06510